User login
Key clinical point: Baseline des-gamma-carboxy prothrombin (DCP) levels and neutrophil-to-lymphocyte ratio (NLR) may serve as predictive biomarkers of survival in patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (ATE+BEV) therapy.
Major finding: Multivariate analysis revealed that a DCP level of ≥186 mAU/mL and an NLR of ≥2.5 independently predict overall survival (adjusted hazard ratio [aHR] 5.102; P < .001; and aHR 3.584; P = .001, respectively) and progression-free survival (aHR 2.311; P = .002; and aHR 1.938; P = .012, respectively).
Study details: The data come from a real-world observational study that included 121 patients with advanced HCC who received ≥1 cycle of ATE+BEV treatment.
Disclosures: This study was sponsored by a National Research Foundation of Korea grant funded by the Korea government. Some authors declared receiving honoraria or research grants from various sources.
Source: Chon YE, Cheon J, et al. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Med. 2022 (Aug 23). Doi: 10.1002/cam4.5161
Key clinical point: Baseline des-gamma-carboxy prothrombin (DCP) levels and neutrophil-to-lymphocyte ratio (NLR) may serve as predictive biomarkers of survival in patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (ATE+BEV) therapy.
Major finding: Multivariate analysis revealed that a DCP level of ≥186 mAU/mL and an NLR of ≥2.5 independently predict overall survival (adjusted hazard ratio [aHR] 5.102; P < .001; and aHR 3.584; P = .001, respectively) and progression-free survival (aHR 2.311; P = .002; and aHR 1.938; P = .012, respectively).
Study details: The data come from a real-world observational study that included 121 patients with advanced HCC who received ≥1 cycle of ATE+BEV treatment.
Disclosures: This study was sponsored by a National Research Foundation of Korea grant funded by the Korea government. Some authors declared receiving honoraria or research grants from various sources.
Source: Chon YE, Cheon J, et al. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Med. 2022 (Aug 23). Doi: 10.1002/cam4.5161
Key clinical point: Baseline des-gamma-carboxy prothrombin (DCP) levels and neutrophil-to-lymphocyte ratio (NLR) may serve as predictive biomarkers of survival in patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (ATE+BEV) therapy.
Major finding: Multivariate analysis revealed that a DCP level of ≥186 mAU/mL and an NLR of ≥2.5 independently predict overall survival (adjusted hazard ratio [aHR] 5.102; P < .001; and aHR 3.584; P = .001, respectively) and progression-free survival (aHR 2.311; P = .002; and aHR 1.938; P = .012, respectively).
Study details: The data come from a real-world observational study that included 121 patients with advanced HCC who received ≥1 cycle of ATE+BEV treatment.
Disclosures: This study was sponsored by a National Research Foundation of Korea grant funded by the Korea government. Some authors declared receiving honoraria or research grants from various sources.
Source: Chon YE, Cheon J, et al. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Med. 2022 (Aug 23). Doi: 10.1002/cam4.5161